HomeGeneticsConditionMucolipidosis III gamma
Back to Condition
Mucolipidosis III gamma
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Mucolipidosis III gamma

Mucolipidosis III gamma is a slowly progressive, rare genetic disorder characterized by skeletal abnormalities, joint stiffness, and a shortened lifespan.

Overview

Mucolipidosis III gamma is a slowly progressive disorder that affects many parts of the body. Signs and symptoms typically appear around age 3. Individuals with this condition generally survive into adulthood, though they may have a shortened lifespan.

Symptoms

  • Slow growth and short stature
  • Stiff joints and pain that worsens over time
  • Dysostosis multiplex (multiple skeletal abnormalities seen on x-ray)
  • Low bone mineral density, leading to weakened bones and fractures
  • Osteoporosis
  • Heart valve abnormalities
  • Mild clouding of the clear covering of the eye (cornea)
  • Slightly thickened or coarse facial features
  • Mild intellectual disability or learning problems in a small percentage of cases

Causes

This condition is caused by mutations in the GNPTG gene. This gene provides instructions for making a subunit of the enzyme GlcNAc-1-phosphotransferase. This enzyme is responsible for "tagging" digestive enzymes with a molecule called mannose-6-phosphate (M6P), which acts as a signal to transport these enzymes to the lysosomes—the cell's recycling compartments.

Mutations in the GNPTG gene reduce the activity of this enzyme, preventing digestive enzymes from reaching the lysosomes. Consequently, large molecules accumulate within the lysosomes, characterizing this as a lysosomal storage disorder.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an affected individual typically carry one copy of the mutated gene but do not show signs or symptoms of the condition.

Other Names

  • ML IIIC
  • Mucolipidosis III
  • Mucolipidosis III, variant
  • Mucolipidosis IIIC
  • Mucolipidosis type III
  • Pseudo-Hurler polydystrophy

Frequently Asked Questions

Children should have a baseline dual‑energy X‑ray absorptiometry (DXA) scan by age 5, followed by repeat scans every 1–2 years to track bone mineral density. Regular orthopedic exams every 6–12 months help detect fractures, scoliosis, or worsening dysostosis multiplex, and vitamin D + calcium supplementation is often recommended based on lab results.
Baseline echocardiography is advised by age 3–4, with repeat studies every 2–3 years or sooner if the child develops shortness of breath, fatigue with activity, new heart murmurs, or swelling of the ankles. Any sudden increase in murmur intensity or signs of heart failure warrants immediate cardiology evaluation.
Carrier couples can consider pre‑implantation genetic testing (PGT‑M) with in‑vitro fertilization to select embryos without two pathogenic GNPTG copies, or prenatal diagnostic testing (chorionic villus sampling or amniocentesis) with the option of pregnancy continuation decisions. Non‑invasive prenatal screening for the specific family mutation is also emerging.
In addition to regular low‑impact stretching and aquatic therapy, clinicians may prescribe NSAIDs or low‑dose tramadol for pain, and consider intra‑articular hyaluronic acid injections for larger joints. Orthopedic surgery (e.g., tendon releases or joint realignment) is evaluated case‑by‑case when contractures severely limit function. Early use of night splints and custom orthotics can also preserve range of motion.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA